Biosimilars User Fee Act
Creates an abbreviated licensure pathway for biologic products that are demonstrated to be “biosimilar” to or “interchangeable” with an FDA-licensed biologic product. This pathway is provided in the part of the law known as the Biologics Price Competition and Innovation Act (BPCI Act).
A title for physicians who have completed all preparatory work (medical school, residency, etc.) and have been approved to practice by a group of their peers.
Individuals who have completed all preparatory work but have not yet been approved to practice medicine on their own.
The lowest actuarial level health plans available through the insurance exchanges, equal to a 60 percent actuarial value. Silver, Gold, and Platinum plans offer varying actuarial values.
Paying for treatment for a medical condition as a single lump sum payment rather than a per-treatment or per-provider payment.